All In Biotech

Drug Trial Radar · NCT06384547

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Thyroid Eye Disease (TED)

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

May 23, 2024

Primary completion

May 1, 2025

Study completion Jan 19, 2026

Sponsor

Lead sponsor
Viridian Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with TED. The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in participants with TED.

Conditions

  • Thyroid Eye Disease

Interventions

  • VeligrotugDrug

    5 infusions of veligrotug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15Time frame: Baseline through Week 15

Locations

50 sites in 7 countries. Site status is shown where the registry gives one.

  • United Medical Research Institute

    Inglewood, California

  • Advancing Research International, LLC

    Los Angeles, California

  • Stanford Byers Eye Institute

    Palo Alto, California

  • Cockerham Eye Consultants, PC

    San Diego, California

  • FOMAT Medical Research

    Santa Maria, California

  • University of Colorado - Dept of Ophthalmology

    Aurora, Colorado

  • Sina Medical Center LLC

    Homestead, Florida

  • Med-Care Research Inc.

    Miami, Florida

  • Edward Jenner Research Group Center LLC

    Plantation, Florida

  • Sarasota Retina Institute

    Sarasota, Florida

  • Vision Medical Research Inc.

    Orland Park, Illinois

  • University Health Diabetes, Endocrinology & Nephrology Center

    Kansas City, Kansas

  • KU Medical Center, University of Kansas

    Kansas City, Kansas

  • Massachusetts Eye and Ear

    Boston, Massachusetts

  • Ophthalmic Consultants of Boston

    Weymouth, Massachusetts

  • Fraser Eye Care Center

    Fraser, Michigan

  • Kahana Oculoplastic & Orbital Surgery

    Livonia, Michigan

  • University of Minnesota, Department of Ophthalmology and Visual Neurosciences

    Minneapolis, Minnesota

  • Advancing Research International, LLC

    Las Vegas, Nevada

  • Rutgers- New Jersey Medical School- Newark

    Newark, New Jersey

  • New York Eye Ear Infirmary of Mount Sinai

    New York, New York

  • Baylor College of Medicine (BCM) - Ophthalmology

    Houston, Texas

  • Neuro-Eye Clinical Trials

    Houston, Texas

  • Neuro-Ophthalmology of Texas, PLLC

    Houston, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • West Virginia University Eye Institute

    Morgantown, West Virginia

  • Sydney Eye Hospital

    Sydney, Australia

  • North Shore Eye Surgery

    Sydney, Australia

  • CHU d'Angers

    Angers, France

  • Centre Hospitalier National D'ophtalmologie

    Des Quinze Vingts Paris, France

  • CH Nice

    Nice, France

  • AP-HP - Hôpital de la Pitié Salpétrière

    Paris, France

  • Universitätsmedizin Göttingen

    Göttingen, Germany

  • Johannes Gutenberg-University Medical Center

    Mainz, Germany

  • NZOZ E-Vita

    Bialystok, Poland

  • Specjalistyczny Osrodek Okulistyczny Oculomedica

    Bydgoszcz, Poland

  • Santa Familia PTG Lodz

    Lódz, Poland

  • Panstwowy Instytut Medyczny MSWiA

    Warsaw, Poland

  • 4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ

    Wroclaw, Poland

  • Clinica Bonanova de Cirugia Ocular

    Barcelona, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.